Chart Events
Performance Outlook
| Previous Close | 10.57 |
| Open | 10.67 |
| Bid | 10.57 x 900 |
| Ask | 10.84 x 900 |
| Day's Range | 10.58 - 10.84 |
| 52 Week Range | 9.77 - 40.70 |
| Volume | |
| Avg. Volume | 5,752 |
| Market Cap | 761.861M |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | 6.34 |
| EPS (TTM) | 1.71 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.34 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
Related Research
- Valneva SEDaily – Vickers Top Buyers & Sellers for 11/22/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
- GlobeNewswire
VALNEVA - Declaration of shares and voting rights - February 28, 2023
VALNEVA Declaration of shares and voting rightsFebruary 28, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: March 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change wa
- Benzinga
Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
As previously announced, Valneva SE (NASDAQ: VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new partnership. However, it is completing the remaining clinical studies and submissions. Last week, the Committee for Medicinal Products for Human Use of the European Medicines Agency backed VLA2001 approval in adults as a booster dose after at least seven months following primary vaccination with VLA2001 (homologous booster dose) or with an adenoviral vector
- GlobeNewswire
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
Saint-Herblain (France), March 2, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated COVID-19 vaccine, VLA2001. As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with regulators. On Febru
